Readystate Asset Management LP Boosts Stock Holdings in Revolution Medicines, Inc. $RVMD

Posted by Stanley Muller on Sep 7th, 2026

Readystate Asset Management LP lifted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 18.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 37,727 shares of the company’s stock after acquiring an additional 5,880 shares during the quarter. Readystate Asset Management LP’s holdings in Revolution Medicines were worth $7,066,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Global Retirement Partners LLC raised its stake in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares in the last quarter. Contravisory Investment Management Inc. bought a new stake in Revolution Medicines during the 2nd quarter valued at $32,000. Johnson Financial Group Inc. purchased a new position in shares of Revolution Medicines in the 2nd quarter valued at $37,000. Arax Advisory Partners bought a new position in shares of Revolution Medicines in the 4th quarter worth $38,000. Finally, Silvant Capital Management LLC purchased a new stake in shares of Revolution Medicines during the 2nd quarter worth $41,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $210.02 on Monday. The company’s 50 day moving average is $196.93 and its two-hundred day moving average is $152.91. The company has a market cap of $45.02 billion, a PE ratio of -23.81 and a beta of 1.40. Revolution Medicines, Inc. has a twelve month low of $39.17 and a twelve month high of $224.31. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the firm earned ($1.31) EPS. Analysts anticipate that Revolution Medicines, Inc. will post -8.83 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RVMD shares. Wolfe Research reiterated an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Needham & Company LLC raised their price target on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a report on Monday, August 31st. Truist Financial boosted their price objective on shares of Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. TD Cowen raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Monday, August 24th. Finally, UBS Group raised their target price on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, August 28th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Revolution Medicines has a consensus rating of “Moderate Buy” and an average price target of $200.74.

Read Our Latest Analysis on Revolution Medicines

Insider Transactions at Revolution Medicines

In other news, insider Mark Goldsmith sold 80,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider directly owned 267,330 shares in the company, valued at $55,925,436. This trade represents a 23.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the completion of the sale, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 268,497 shares of company stock valued at $49,587,926. 7.60% of the stock is owned by company insiders.

About Revolution Medicines

(Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.